Roche Holding AG (RHHBY)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...

Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Don...

Roche Pharmaceuticals' CEO told investors she was "serious" about the goal of becoming a top 3 obesity player. The drugmaker's CT-388 weight loss injection is entering a phase III trial, marking the l...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton's tyrosin...

Roche Holding AG - Special Call Company Participants Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Levi Garraway - Executive VP, Head of Gl...

Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes compe...

Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs pose to the cruci...

Shares in Roche Holding rose around 2% on Monday, outperforming a broadly unchanged European healthcare index , as the drugmaker said it was advancing its experimental obesity drug CT-388 to a late-st...

The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free survival in patients with advanced breast cancer.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigat...